COMPANY
89bio
89bio is listed on ClinicalTrials.gov as the lead sponsor of 7 studies; the most recently updated is “A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)” (Phase 3, recruiting), in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis. From public records Source · Oct 12, 2026